Pulmonx shares surge 10.06% after-hours as leadership changes and Buy ratings from Stifel, Canaccord boost investor confidence.

Pulmonx surged 10.06% in after-hours trading following the return of former CEO Glen French and CFO Derrick Sung, which analysts at Stifel and Canaccord Genuity cited as a positive catalyst, reiterating "Buy" ratings with price targets of $5 and $6, respectively. The stock’s rise also aligned with third-quarter revenue of $21.5 million, exceeding expectations, and a strategic partnership with Jaeger Medical to enhance clinical data integration. Despite Lake Street lowering its price target to $4, broader analyst optimism about leadership stability, clinical validation of Zephyr valves, and long-term growth potential drove the sharp after-hours gain. The company’s revised full-year guidance, emphasizing confidence in achieving targets, further reinforced investor confidence in its path to profitability.